| Pfizer Inc (PFE) | |||
|---|---|---|---|
| 24.72 -0.36 (-1.44%) | 06-23 15:59 | ||
| Open: | 25 | Pre. Close: | 25.08 |
| High: | 25.235 | Low: | 24.695 |
| Volume: | 56,375,384 | Market Cap: | 140,890(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 30.18  One year: 31.00 |
| Support: | Support1: 24.69 Support2: 20.55 |
| Resistance: | Resistance1: 25.84 Resistance2: 26.54 |
| Pivot: | 25.66 |
| Moving Averages: | MA(5): 25.40 MA(20): 25.75 MA(100): 26.34 MA(250): 24.87  |
| MACD: | MACD(12,26): -0.19 Signal(12,26,9): -0.10 |
| %K %D: | %K(14,3): 9.50 %D(3): 26.76 |
| RSI: | RSI(14): 33.74 |
| 52-Week: | High: 28.75 Low: 23.11 Change(%): 8.8 |
| Average Vol(K): | 3-Month: 35921 10-Days: 39663 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 25.278 - 25.454 | 25.454 - 25.59 |
| Low: | 24.227 - 24.467 | 24.467 - 24.651 |
| Close: | 24.39 - 24.713 | 24.713 - 24.961 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PFE ] has closed below the lower bollinger band by 6.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ PFE ] is to continue within current trading range. Bollinger Bands are 9.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - General | |
| Shares Out. (M) | 5700.00 |
| Shares Float (M) | 5690.00 |
| % Held by Insiders | 0.10 |
| % Held by Institutions | 69.38 |
| Shares Short (K) | 162660 |
| Shares Short Prior Month (K) | 140320 |
| Stock Financials | |
|---|---|
| EPS | 1.310 |
| Book Value (p.s.) | 15.810 |
| Profit Margin | 11.83 |
| Operating Margin | 31.62 |
| Return on Assets (ttm) | 5.7 |
| Return on Equity (ttm) | 8.3 |
| Qtrly Rev. Growth | 5.4 |
| Gross Profit (p.s.) | 8.309 |
| Sales Per Share | 11.109 |
| EBITDA (p.s.) | 4.467 |
| Qtrly Earnings Growth | -10.10 |
| Operating Cash Flow (M) | 11980.00 |
| Levered Free Cash Flow (M) | 12380.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | 18.87 |
| PEG Ratio | 13.77 |
| Price to Book value | 1.56 |
| Price to Sales | 2.22 |
| Price to Cash Flow | 11.76 |
| Stock Dividends | |
|---|---|
| Dividend | 0.430 |
| Dividend Yield | 0.02 |
| Dividend Growth | |
